Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab - Phase 2

What this Trial Is About

Researchers are evaluating a virtual reality (VR) program called Survivors' Virtual Reality Survivorship Experience (SurviVRSE) designed to educate breast cancer survivors about heart health. This study focuses on survivors who have received anthracyclines or trastuzumab, treatments known to potentially affect heart function. The goal is to test how easy, feasible, and acceptable the VR intervention is for participants, and to explore whether it improves knowledge about cancer therapy related cardiac dysfunction (CTRCD) and promotes heart-healthy behaviors like physical activity. Participants will receive access to the VR cardiovascular health education and gaming intervention during a treatment infusion. The VR content covers potentially cardiotoxic treatments, how to recognize treatment-related heart problems, and heart-healthy lifestyle changes survivors can adopt. Before starting, participants will complete a baseline survey, then go through the VR education modules and games during one infusion session. Afterward, they will complete a similar survey within two days and a final survey one month later. Throughout the study, researchers will measure participants' knowledge of CTRCD at baseline, shortly after the intervention, and four weeks later. They will also assess usability, acceptability, user satisfaction, physical activity, sleep quality, tobacco use, and intent to change behavior. The entire participation involves completing surveys around the VR session and follow-up assessments, allowing researchers to evaluate the impact of the VR program on breast cancer survivors' heart health awareness and behaviors.

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab